In the 2020 American Society of Clinical Oncology (ASCO), a multicenter study including an ICI cohort of different cancer species showed that the ORR in patients with LRP1B mutations was significantly higher than that in wild-type patients (57% vs 18%), independent of TMB/microsatellite instability (MSI) status. Here, LRP1B is linked to cancer.